Suraksha Diagnostic Ltd

SURAKSHA NSE Healthcare Healthcare Service Provider
₹323.75
-1.25%
Delayed · cached 15 min

Fair value analysis

SURAKSHA
Suraksha Diagnostic Ltd
HealthcareHealthcare Service Provider
₹327.85
Close used for this calculation
₹198.11Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
34/100
Profitability8/25
Returns8/25
Balance Sheet14/25
Efficiency4/25
Growth0/25
Weak
Quality radar
34Prof.8/25Ret.8/25Eff.4/25B.Sht14/25Growth0/25

Consensus fair value

₹198.11
Above FV
▼ -39.6% against the close used
Model range ₹54.67 – ₹259.87
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹54.67Fair value₹198.11Bull₹259.87
FairClose
52-week traded range
52W low ₹227.9552W high ₹340.80

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Suraksha Diagnostic Ltd closed at ₹327.85, 65.5% above the consensus fair value of ₹198.11 drawn from 7 valuation models.

Financial DNA score 34/100 — Weak. P/E of 47.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹54.67
-83.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹85.82
-73.8%
√(22.5 × EPS × BVPS)
EPS=6.18, BVPS=52.96 · outside Graham range (P/E 47.1, P/B 6.2) — asset-light, treat as a rough floor
P/E Fair Value
₹259.87
-20.7%
EPS × 42.05x (sector P/E)
EPS=6.18, Sector P/E=42.05x
EV/EBITDA
₹241.12
-26.5%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=1.37B
Book Value (P/B)
₹84.74
-74.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=52.96, ROE=14.2%, g=3%, r=10%
Reverse DCF
₹327.85
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 20.3% | Historical: 0%
Margin of Safety
₹100.09
-69.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=133.45, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.